SW033291

SW033291 is a **potent small molecule inhibitor** of **15-hydroxyprostaglandin dehydrogenase (15-PGDH)**, an enzyme that mediates the degradation of prostaglandin E2 (PGE2). By inhibiting 15-PGDH, SW033291 elevates tissue levels of PGE2, resulting in enhanced tissue regeneration, protection against age-related organ failure, and potential metabolic and neuroprotective effects. Preclinical studies have shown SW033291: - **Mitigates cardiac fibrosis and improves cardiac function** in aged mice. - **Promotes liver regeneration** and protects against acetaminophen-induced liver injury in mice. - **Promotes hematopoietic recovery** after bone marrow transplant by enhancing the bone marrow stem cell niche. - **Improves glucose tolerance and hepatic steatosis** in models of Type 2 diabetes mellitus, acting in part via the PGE2 receptor EP4. - **Protects the blood-brain barrier and mitigates cognitive decline** in mouse models of Alzheimer's disease by blocking pathological 15-PGDH activity in the brain. Developed by academic researchers from Case Western Reserve University and the University of Texas Southwestern Medical Center, with Rodeo Therapeutics Corp. as a commercial partner, SW033291 is currently in **preclinical development** and has not yet entered human clinical trials[1][2][3][4][5][8].

Other names

SW033291SW-033291SW 033291